Date June 24, 2009 Contacts Mike Ferrari Phone 216.844.7239 News Release Department
of Marketing and Communications 11100 Euclid Avenue Cleveland, OH 44106

CLEVELAND – University
Hospitals Case Medical Center has been selected by Telesso Technologies Limited,
a global healthcare company, as the second site to enroll patients in a
head-to-head trial evaluating its FDA-approved guide wire-assisted peripheral
IV catheter versus the industryÕs gold standard device for peripheral IV
placement.
A
peripheral vein is the most common site for insertion of a catheter for
short-term diagnostic or therapeutic use. The catheter is placed into the
peripheral vein in the arm, below the elbow and is typically passed up inside
the vein to a length of 2-3 inches.
TelessoÕs uniquely-designed guide wire-assisted
peripheral IV catheter device uses a retractable guide wire system that is
believed to enable easier IV access, reduce common safety risks, significantly
lessen patient pain and discomfort, and provide cost savings to facilities by
lowering administrative costs associated with failed IV starts.
End
results for the trial could lead to the device being the first clinically
meaningful advancement in peripheral IV access since automatic needle
retraction catheters and addresses significant unmet needs in peripheral
intravenous access. The clinical
trial is being conducted at the Surgical Intensive Care Unit (SICU) under
Principal Investigator Dr. James Rowbottom, Vice-Chair,
Clinical Affairs and CO-Chief SICU; Department of Anesthesiology & Perioperative Medicine, UHCMC.
UHCMCÕs Bette Idemoto, PhD, RN, the other Principal
Investigator of the trial.
ÒWe
are honored to have been selected by the company as a trial site as it affirms
our standing in the country,Ó she said. ÒThis is very exciting for University
Hospitals Case Medical Center. The device is so easy to use and intuitive. I
canÕt wait for it to be in full production so we can use it across the
hospital.Ó
The
trial will enroll approximately 400 pediatric, geriatric and oncology patients
at three world-class sites who will be treated with either the novel guide-wire
assisted peripheral IV catheter or the current standard of care.
ÒThis
post-market study represents the advancement of an important innovation in
medicine designed to reduce the safety risks and costs traditionally associated
with peripheral IV catheter use, and improve patient care,Ó said TelessoÕs CEO Nelson Stacks. ÒWe are very excited to add University
Hospitals Case Medical Center to our trial as it is a world renowned medical
facility.Ó
***
About University
Hospitals
With 150 locations throughout
Northeast Ohio, University Hospitals serves the needs of patients through an
integrated network of hospitals, outpatient centers and primary care physicians. At the core of our health system is
University Hospitals Case Medical Center.
The primary affiliate of Case Western Reserve University School of
Medicine, University Hospitals Case Medical Center is home to some of the most
prestigious clinical and research centers of excellence in the nation and the
world, including cancer, pediatrics, women's health, orthopedics and spine,
radiology and radiation oncology, neurosurgery and neuroscience, cardiology and
cardiovascular surgery, organ transplantation and human genetics. Its main
campus includes the internationally celebrated UH Rainbow Babies &
Children's Hospital, ranked among the top hospitals in the nation; UH MacDonald
Women's Hospital, Ohio's only hospital for women; and UH Ireland Cancer Center,
a part of the NCI-designated Case Comprehensive Cancer Center, which holds the
nation's highest designation by the National Cancer Institute of Comprehensive
Cancer Center. For more information, go to www.uhhospitals.org.
For more information, visit TelessoÕs web site
at http://www.telesso.com
CONTACT: Nelson K. Stacks, CEO, +1.781.718.7742, or Ian Atkin,
Chief Financial Officer, Australia +61 2 9805 0022, both of Telesso Technologies